If approved company’s prostate cancer therapy will be the first dual-action tablet available in EU

Updated Date: Fri, 17 Feb 2023 00:00:00 EST

Updated Date: Fri, 17 Feb 2023 00:00:00 EST

Updated Date: Fri, 17 Feb 2023 00:00:00 EST

Updated Date: Fri, 17 Feb 2023 00:00:00 EST

Updated Date: Fri, 17 Feb 2023 00:00:00 EST

Treatment is an BTK inhibitor and has demonstrated a sound safety and tolerability profile

Africa-based trials for blood test which detects risk of disease progression are due to begin

Phase 1/2 research shows that treatment could be very effective against Fabry disease

Next phase of Newel Health’s digital therapeutics solution for Parkinson’s disease gains vital grant